Phase II trials have shown that iptacopan eliminated intravascular hemolysis in PNH patients and reduced extravascular hemolysis in patients with persistent anemia who had been treated with C5 complement inhibitors (8, 9). The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.